Omnicell (NASDAQ:OMCL) Releases FY 2025 Earnings Guidance

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Omnicell (NASDAQ:OMCL - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 1.400-1.650 for the period, compared to the consensus earnings per share estimate of 1.278. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.1 billion. Omnicell also updated its Q3 2025 guidance to 0.300-0.370 EPS.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on OMCL. Wells Fargo & Company lifted their price target on Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a report on Monday, July 21st. Bank of America lifted their price target on Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a report on Friday, May 23rd. Piper Sandler reissued an "overweight" rating on shares of Omnicell in a research report on Friday, May 23rd. Benchmark reduced their price objective on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, Wall Street Zen raised Omnicell from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 12th. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Omnicell has an average rating of "Moderate Buy" and a consensus price target of $45.33.

Omnicell Stock Up 1.7%

OMCL traded up $0.51 during trading on Monday, reaching $30.27. 48,591 shares of the stock traded hands, compared to its average volume of 564,751. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of 60.50, a price-to-earnings-growth ratio of 8.69 and a beta of 0.78. Omnicell has a fifty-two week low of $22.66 and a fifty-two week high of $55.74. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24. The stock's 50-day simple moving average is $29.27 and its two-hundred day simple moving average is $33.05.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, topping analysts' consensus estimates of $0.30 by $0.15. Omnicell had a return on equity of 4.27% and a net margin of 2.01%. The company had revenue of $290.56 million during the quarter, compared to analysts' expectations of $275.57 million. During the same quarter in the previous year, the firm earned $0.51 earnings per share. The business's quarterly revenue was up 5.0% compared to the same quarter last year. As a group, equities research analysts expect that Omnicell will post 1.09 EPS for the current year.

Institutional Trading of Omnicell

A number of institutional investors and hedge funds have recently made changes to their positions in OMCL. Jane Street Group LLC lifted its position in shares of Omnicell by 201.5% during the 1st quarter. Jane Street Group LLC now owns 163,664 shares of the company's stock worth $5,722,000 after purchasing an additional 109,382 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Omnicell by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company's stock valued at $4,337,000 after acquiring an additional 4,866 shares in the last quarter. AQR Capital Management LLC raised its holdings in Omnicell by 42.1% in the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company's stock valued at $627,000 after acquiring an additional 5,311 shares in the last quarter. Finally, Empowered Funds LLC raised its holdings in Omnicell by 14.3% in the 1st quarter. Empowered Funds LLC now owns 9,953 shares of the company's stock valued at $348,000 after acquiring an additional 1,243 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company's stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.